Chapter 14 Advances in the Discovery of CC Chemokine Receptor 2 Antagonists

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Annual Reports in Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0065-7743(07)42014-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CCL2‐independent role of CCR2 in immune responses against Leishmania major

  2007cited by this paper
• Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice

  2007cited by this paper
• Novel, Acidic CCR2 Receptor Antagonists: From Hit to Lead

  2007cited by this paper
• α-Aminothiazole-γ-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists

  2007cited by this paper
• Obesity induces a phenotypic switch in adipose tissue macrophage polarization.

  2007cited by this paper
• CCR2 expression correlates with prostate cancer progression

  2007cited by this paper
• Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

  2007cited by this paper
• Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.

  2007cited by this paper
• Increased Inflammatory Properties of Adipose Tissue Macrophages Recruited During Diet-Induced Obesity

  2007cited by this paper
• Absence of the Chemokine Receptor CCR2 Protects Against Cerebral Ischemia/Reperfusion Injury in Mice

  2007cited by this paper
• Advances in Anti-Inflammatory Therapeutics

  2007cited by this paper
• Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease

  2007cited by this paper
• CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.

  2007cited by this paper
• Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2.

  2007cited by this paper
• Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites.

  2007cited by this paper
• A novel activator of C-C chemokine, FROUNT, is expressed with C-C chemokine receptor 2 and its ligand in failing human heart.

  2007cited by this paper
• Can we target the chemokine network for cancer therapeutics?

  2006cited by this paper
• 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.

  2006cited by this paper
• The many roles of chemokines and chemokine receptors in inflammation.

  2006cited by this paper
• CCR2 modulates inflammatory and metabolic effects of high-fat feeding.

  2006cited by this paper
• Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists

  2006cited by this paper
• Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2

  2006cited by this paper
• The CCR2 receptor as a therapeutic target

  2006cited by this paper
• Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.

  2006cited by this paper
• Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance*

  2006cited by this paper
• Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion

  2006cited by this paper
• CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium

  2006cited by this paper
• MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity.

  2006cited by this paper
• GluVII:06--a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors.

  2006cited by this paper
• A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

  2006cited by this paper
• The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis

  2005cited by this paper
• Repopulation of Apolipoprotein E Knockout Mice With CCR2-Deficient Bone Marrow Progenitor Cells Does Not Inhibit Ongoing Atherosclerotic Lesion Development

  2005cited by this paper
• Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma.

  2005cited by this paper
• Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

  2005cited by this paper
• Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.

  2005cited by this paper
• Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis

  2005cited by this paper
• Diet induction of monocyte chemoattractant protein-1 and its impact on obesity.

  2005cited by this paper
• 2-Mercaptoimidazoles, a new class of potent CCR2 antagonists.

  2005cited by this paper
• Inflamed fat: what starts the fire?

  2005cited by this paper
• The presence of leukocyte CC-chemokine receptor 2 in CCR2 knockout mice promotes atherogenesis.

  2005cited by this paper
• Monocyte and macrophage heterogeneity

  2005cited by this paper
• Dual Role of CCR2 during Initiation and Progression of Collagen-Induced Arthritis: Evidence for Regulatory Activity of CCR2+ T Cells1

  2004cited by this paper
• Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives.

  2004cited by this paper
• CCL2 (monocyte chemoattractant protein-1) and cancer.

  2004cited by this paper
• Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis.

  2004cited by this paper
• N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor.

  2004cited by this paper
• CCR2-Dependent Trafficking of F4/80dim Macrophages and CD11cdim/intermediate Dendritic Cells Is Crucial for T Cell Recruitment to Lungs Infected with Mycobacterium tuberculosis1

  2004cited by this paper
• Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives.

  2004cited by this paper
• Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice.

  2004cited by this paper
• Targeting monocyte chemoattractant protein-1 signalling in disease

  2003cited by this paper
• Transplantation of Monocyte CC-Chemokine Receptor 2-Deficient Bone Marrow Into ApoE3-Leiden Mice Inhibits Atherogenesis

  2003cited by this paper
• Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2

  2003cited by this paper
• Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice.

  2003cited by this paper
• Blood monocytes consist of two principal subsets with distinct migratory properties.

  2003cited by this paper
• CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.

  2003cited by this paper
• Unraveling the chemistry of chemokine receptor ligands.

  2003cited by this paper
• An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice

  2003cited by this paper
• Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains.

  2003cited by this paper
• New therapeutics that modulate chemokine networks

  2002cited by this paper
• Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong?

  2002cited by this paper
• Monocyte Chemoattractant Protein-1 Deficiency is Protective in a Murine Stroke Model

  2002cited by this paper
• Mycobacterium tuberculosis in Chemokine Receptor 2-Deficient Mice: Influence of Dose on Disease Progression

  2002cited by this paper
• Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis

  2001cited by this paper
• Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.

  2001cited by this paper
• Chemokine Receptor Expression and Function in CD4+ T Lymphocytes with Regulatory Activity1

  2001cited by this paper
• Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists

  2000cited by this paper
• Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.

  2000cited by this paper
• CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.

  2000cited by this paper
• A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

  2000cited by this paper

• Synthesis, 3H‐labelling and in vitro evaluation of a substituted dipiperidine alcohol as a potential ligand for chemokine receptor 2

  2019cites this paper
• Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.

  2016cites this paper
• Stereoselective Bulk Synthesis of CCR2 Antagonist BMS-741672: Assembly of an All-cis (S,R,R)-1,2,4-Triaminocyclohexane (TACH) Core via Sequential Heterogeneous Asymmetric Hydrogenations

  2016cites this paper
• Chemokines: Chemokines and Their Receptors in Drug Discovery

  2015cites this paper
• Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.

  2014cites this paper
• Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview

  2014influential citation
• Chemokine Receptors in Allergy, Inflammation, and Infectious Disease

  2014cites this paper
• Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 – 2012

  2013cites this paper
• Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.

  2012cites this paper
• Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.

  2012cites this paper
• Chemokine receptor antagonists.

  2012cites this paper
• Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).

  2012cites this paper
• Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.

  2011cites this paper
• Nouveaux antagonistes du récepteur ccr2, leur procédé de production et leur utilisation en tant que médicaments

  2011cites this paper
• Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.

  2011cites this paper
• Spiroindenes and spiroindanes as antagonists of CC chemokine receptor 2: WO 2009023754

  2010cites this paper
• Agents Acting on Prostanoid and Thromboxane Receptors

  2010cites this paper
• Role of Chemistry in Lead Discovery

  2010cites this paper
• gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.

  2010cites this paper
• CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis

  2009cites this paper
• Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.

  2009cites this paper
• Chemokine receptor antagonists: overcoming developmental hurdles

  2009cites this paper
• Synthesis and evaluation of cis-3,4-disubstituted piperidines as potent CC chemokine receptor 2 (CCR2) antagonists.

  2008cites this paper
• Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.

  2008cites this paper